ReviewBiology2026
Rewiring Biological Barriers in Pancreatic Diseases with Metal-Organic Frameworks.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic diseases, particularly pancreatic ductal adenocarcinoma (PDAC), remain among the most challenging disorders to diagnose and treat owing to a series of interconnected biological barriers, including dense stromal desmoplasia, profound immunosuppression, hypoxia, therapeutic resistance, and the lack of effective early-detection strategies. Overcoming these barriers requires multifunctional platforms capable of integrating diagnosis, microenvironment regulation, and precision therapy within a single system. Metal-organic frameworks (MOFs), a class of highly tunable porous crystalline materials, have emerged as uniquely suited candidates for this purpose because of their programmable composition, structural versatility, catalytic activity, and capacity for multifunctional integration. Notably, MOFs have evolved from passive drug carriers into active regulators of disease-associated biological processes, enabling enhanced drug delivery, extracellular matrix remodeling, ferroptosis- and cuproptosis-based precision therapy, energy-triggered reactive oxygen species generation, immune microenvironment reprogramming, and imaging-guided theranostics. Beyond pancreatic cancer, emerging evidence further supports their potential applications in pancreatitis management and interventional therapeutic enhancement. In this review, we systematically summarize recent advances in the rational engineering of MOFs for pancreatic diseases, focusing on how material design strategies are leveraged to overcome key pathological barriers and improve therapeutic outcomes. We further discuss current challenges associated with biosafety, biodegradation, large-scale manufacturing, and clinical translation, while highlighting future opportunities for the development of next-generation MOF-based precision nanomedicines. By integrating advances across materials science, nanomedicine, and pancreatic disease biology, this review provides a comprehensive framework for the design and translational development of MOF-enabled diagnostic and therapeutic platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.